Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer

Status: Recruiting
Location: See location...
Intervention Type: Drug, Dietary supplement, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation, including an observational arm to describe response in patients who are not deficient. Investigators hypothesize that vitamin D supplementation during neoadjuvant chemotherapy in operable triple negative breast cancer patients with vitamin D deficiency, will increase the rate of pathologic complete response chain reaction to that of vitamin D sufficient patients based on historical controls.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Women or men with histologically confirmed invasive mammary carcinoma.

• Known triple negative ER/PR/HER2 receptor status as defined by:

‣ ER and PR less than or equal to 10% and

⁃ HER2 negative based on one of the following:

⁃ IHC 0 or 1+

⁃ IHC 2+ and FISH negative

⁃ IHC 2+ and FISH equivocal and no indication for HER2 targeted therapy based on the treating investigators discretion (i.e., HER2: CEP17 ratio \< 2.0 or HER2 total copy number \<6)

• Patients who plan to undergo neoadjuvant chemotherapy prior to definitive surgical management. Participants are eligible up to 2 weeks after initiating neoadjuvant chemotherapy.

• ECOG performance status of 0, 1 or 2.

• Age ≥ 18.

• The effects of high dose vitamin D on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).

Locations
United States
North Carolina
Wake Forest Baptist Health Sciences
RECRUITING
Winston-salem
Contact Information
Primary
Study Coordinator
jwyche@wakehealth.edu
336-713-0031
Time Frame
Start Date: 2021-10-22
Estimated Completion Date: 2026-03
Participants
Target number of participants: 50
Treatments
Experimental: Vitamin D Supplementation Group - Deficient Levels
Along with standard of care neoadjuvant chemotherapy treatments and procedures, participants will receive oral 50,000 international units of Vitamin D3 supplementation at the initiation of chemotherapy once a week.
Active_comparator: Observational Arm - Vitamin D at Normal Levels
Standard of care neoadjuvant chemotherapy
Sponsors
Leads: Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov